Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients

Study Overview
=================
Brief Summary
-----------------
The objective of this prospective study is to evaluate the prevalence of neurocognitive impairments in HIV infected patients comparing patients with and without HAART. Recent studies have demonstrated a specific HIV infected patients neurocognitive disorders profile. These cognitive disorders concern primarily information processing speed, memory recall, attentional abilities, work related memory, executive functions, and psychometrical speed. This cognitive profile is similar to another highly documented one, described for another central nervous system disease (CNS): multiple sclerosis. In both CNS diseases, the earliest and most severe disorder is the one related to the information processing speed. For the multiple sclerosis patients, a short cognitive test (SDMT) is actually used not only to identify cognitive disorders presence, but also in order to predict a long term disability worsening. A digital version of this test (CSCT), has recently been developed in order to make this early evaluation easier. We hypothesize that CSCT alteration would also predict HAND, in HIV infected patients. A complete neuropsychological assessment is highly time and personal consuming. This short (approximatively 2 minutes) digital test would be highly helpful to identify patients, who will need a more extensive neuropsychological assessment.

Official Title
-----------------
Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients

Conditions
-----------------
HIV-1

Intervention / Treatment
-----------------
* Other: Classic evaluation of neurocognitive functions
* Other: New evaluation of neurocognitive functions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients infected with HIV-1 Patients followed in outpatient service, over 18 years of age Exclusion Criteria: Patients infected with HIV-2 Patients with difficulty understanding the French language Patients present with progressive opportunistic infection Patients for whom a change of psychotropic treatment was performed in the last 3 weeks Patients with drug and / or alcohol addiction Patients with a history of psychiatric disorder Patients with stroke, endocarditis or meningoencephalitis with severe neurological sequelae

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Absence of cognitive disorder<br> | Other: Classic evaluation of neurocognitive functions<br>* Symbol Digit Modalities Test (SDMT)<br>Other: New evaluation of neurocognitive functions<br>* Cognitive Speed Computerized Test (CSCT)<br>|
| Asymptomatic cognitive disorder<br> | Other: Classic evaluation of neurocognitive functions<br>* Symbol Digit Modalities Test (SDMT)<br>Other: New evaluation of neurocognitive functions<br>* Cognitive Speed Computerized Test (CSCT)<br>|
| Symptomatic cognitive impairment<br> | Other: Classic evaluation of neurocognitive functions<br>* Symbol Digit Modalities Test (SDMT)<br>Other: New evaluation of neurocognitive functions<br>* Cognitive Speed Computerized Test (CSCT)<br>|
| HIV associated dementia<br> | Other: Classic evaluation of neurocognitive functions<br>* Symbol Digit Modalities Test (SDMT)<br>Other: New evaluation of neurocognitive functions<br>* Cognitive Speed Computerized Test (CSCT)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive Speed Computerized Test (CSCT) score | allows the evaluation of the speed of the processing of the information | at patient inclusion | 
| Montreal Cognitive Assessment (MoCA) Score | allows the evaluation of the overall cognitive functioning | at patient inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Paced Auditory Serial Addition Test (PASAT) score | allows to evaluate the concentration capacity | at patient inclusion | 
| Numeric Memory (WAIS-III location and back) | short-term memory evaluation and verbal working memory | at patient inclusion | 
| Score RL-RI16 | allows the evaluation of episodic and long-term verbal memory | at patient inclusion | 
| Rey figure | allows the evaluation of the long-term capacities of visio-construction (wealth score) and planning | at patient inclusion | 
| TMTB - TMTA Time Score | Assessment of Mental Flexibility | at patient inclusion | 
| Verbal fluency test | allows the evaluation of the verbal initiation and verbal language capacities | at patient inclusion | 
| IADL score | allows to evaluate the symptomatic character of the disorders | at patient inclusion |